Jethro Holter
Voorzitter bij GENETIC ANALYSIS
Vermogen: 196 394 $ op 31-05-2024
Momenteel actieve connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Ronny Hermansen | M | 62 | 10 jaar | |
| Eilert Aamodt | M | 54 | 3 jaar | |
| Rune Sørum | M | 68 | 14 jaar | |
| Rolf Einar Engstad | M | 65 |
Biotec BetaGlucans AS
 Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million. | - |
| Christina Casèn | F | 64 | 15 jaar | |
| Olav Lanes | M | 52 |
ArcticZymes AS
 ArcticZymes AS Medical SpecialtiesHealth Technology Part of ArcticZymes Technologies ASA, ArcticZymes AS is a Norwegian company that manufactures diagnostic substances. The company is based in Tromsø, Norway. Jethro Holter has been the CEO of the company since 2015. | 14 jaar |
| Gerd Nilsen | M | 56 |
ArcticZymes AS
ArcticZymes AS Medical SpecialtiesHealth Technology Part of ArcticZymes Technologies ASA, ArcticZymes AS is a Norwegian company that manufactures diagnostic substances. The company is based in Tromsø, Norway. Jethro Holter has been the CEO of the company since 2015. | 14 jaar |
| Børge Sørvoll | M | 49 |
Biotec BetaGlucans AS
Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million. | - |
| Camilla Huse Bondesson | M | 66 | 4 jaar | |
| Marit Sjo Lorentzen | M | 56 |
Biotec BetaGlucans AS
Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million. | - |
| Kari Furu | M | 44 | 8 jaar | |
| Lars Tiller | M | - | 2 jaar | |
| Dirk Hahneiser | M | 56 | 2 jaar | |
| Darren Ellis | M | - | 2 jaar | |
| Michael Akoh | M | - | 1 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Svein Wilhelm Faye Lien | M | 70 | 7 jaar | |
| Martin Hunt | M | 66 | - | |
| Volker Wedershoven | M | - | - | |
| Kjersti Grimsrud | F | 63 | 4 jaar | |
| Richard Stuart Godfrey | M | 58 | - | |
| Arne Reinemo | M | - | - | |
| Inger Rydin | F | 67 | 5 jaar | |
| Christian Jørgensen | M | 65 | 2 jaar | |
| Per Matsson | M | 70 | - |
Statistieken
| Land | Connecties | % van het totaal |
|---|---|---|
| Noorwegen | 24 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Jethro Holter
- Persoonlijk netwerk
